Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
Apogee Therapeutics (Nasdaq: APGE) has announced an upcoming poster presentation at the American College of Allergy, Asthma & Immunology's (ACAAI) 2024 Annual Scientific Meeting in Boston from October 24-28, 2024. The presentation will showcase data up to 9 months from the ongoing Phase 1 clinical trial of APG777, a novel half-life extended anti-IL-13 antibody for treating atopic dermatitis and other inflammatory diseases.
The poster, titled "APG777, anti-IL-13 monoclonal antibody, demonstrates extended half-life and sustained inhibition of Type 2 inflammatory biomarkers," will be presented on Friday, October 25, from 2:00-6:00 p.m. ET at the Hynes Convention Center. The presentation will be available on Apogee's website on October 24.
Apogee Therapeutics (Nasdaq: APGE) ha annunciato una prossima presentazione di un poster durante il Meeting Scientifico Annuale del College Americano di Allergia, Asma e Immunologia (ACAAI) del 2024 che si terrà a Boston dal 24 al 28 ottobre 2024. La presentazione mostrerà dati fino a 9 mesi dal corrente studio clinico di Fase 1 di APG777, un nuovo anticorpo anti-IL-13 con estensione della vita ematica per il trattamento della dermatite atopica e di altre malattie infiammatorie.
Il poster, intitolato "APG777, anticorpo monoclonale anti-IL-13, dimostra un prolungamento della vita ematica e un'inibizione sostenuta dei biomarcatori infiammatori di Tipo 2," sarà presentato venerdì 25 ottobre, dalle 14:00 alle 18:00 ET presso il Centro Convegni Hynes. La presentazione sarà disponibile sul sito web di Apogee il 24 ottobre.
Apogee Therapeutics (Nasdaq: APGE) ha anunciado una próxima presentación de un póster en el Encuentro Científico Anual del Colegio Americano de Alergia, Asma e Inmunología (ACAAI) 2024 en Boston del 24 al 28 de octubre de 2024. La presentación mostrará datos de hasta 9 meses del ensayo clínico de Fase 1 en curso de APG777, un nuevo anticuerpo anti-IL-13 con vida media prolongada para el tratamiento de la dermatitis atópica y otras enfermedades inflamatorias.
El póster, titulado "APG777, anticuerpo monoclonal anti-IL-13, demuestra vida media prolongada e inhibición sostenida de los biomarcadores inflamatorios tipo 2," se presentará el viernes 25 de octubre, de 2:00 p.m. a 6:00 p.m. ET en el Centro de Convenciones Hynes. La presentación estará disponible en el sitio web de Apogee el 24 de octubre.
Apogee Therapeutics(Nasdaq: APGE)는 2024년 10월 24일부터 28일까지 보스턴에서 열리는 미국 알레르기, 천식 및 면역학회(ACAAI) 연간 과학 회의에서 포스터 발표를 예정하고 있다고 발표했습니다. 이번 발표에서는 APG777의 진행 중인 1상 임상 시험에서 9개월까지의 데이터를 선보일 예정이며, 이는 아토피 피부염 및 기타 염증성 질환 치료를 위한 새로운 반감기 연장형 항-IL-13 항체입니다.
"APG777, 항-IL-13 단클론 항체, 연장된 반감기 및 제2형 염증 바이오마커의 지속적인 억제를 보여준다"라는 제목의 포스터는 10월 25일 금요일, 오후 2시부터 6시(동부 표준시)까지 하인즈 컨벤션 센터에서 발표됩니다. 발표 자료는 10월 24일 Apogee 웹사이트에서 확인할 수 있습니다.
Apogee Therapeutics (Nasdaq: APGE) a annoncé une prochaine présentation de poster lors de la Réunion Scientifique Annuelle du Collège Américain d'Allergie, d'Asthme et d'Immunologie (ACAAI) de 2024 qui se tiendra à Boston du 24 au 28 octobre 2024. La présentation mettra en avant des données jusqu'à 9 mois de l'essai clinique de Phase 1 de APG777, un nouvel anticorps anti-IL-13 à durée de vie prolongée pour le traitement de la dermatite atopique et d'autres maladies inflammatoires.
Le poster, intitulé "APG777, anticorps monoclonal anti-IL-13, démontre une durée de vie prolongée et une inhibition soutenue des biomarqueurs inflammatoires de type 2," sera présenté le vendredi 25 octobre, de 14h00 à 18h00 ET au Hynes Convention Center. La présentation sera disponible sur le site web d'Apogee le 24 octobre.
Apogee Therapeutics (Nasdaq: APGE) hat eine bevorstehende Posterpräsentation auf dem Jahreswissenschaftlichen Treffen des American College of Allergy, Asthma & Immunology (ACAAI) 2024 in Boston vom 24. bis 28. Oktober 2024 angekündigt. Bei der Präsentation werden Daten von bis zu 9 Monaten aus der laufenden Phase-1-Studie zu APG777, einem neuartigen, mit einer verlängerten Halbwertszeit versehenen Anti-IL-13-Antikörper zur Behandlung von atopischer Dermatitis und anderen entzündlichen Erkrankungen, vorgestellt.
Das Poster mit dem Titel "APG777, Anti-IL-13-Monoklonaler Antikörper, zeigt verlängerte Halbwertszeit und nachhaltige Hemmung von entzündlichen Biomarkern des Typs 2" wird am Freitag, den 25. Oktober, von 14:00 bis 18:00 Uhr ET im Hynes Convention Center präsentiert. Die Präsentation wird am 24. Oktober auf der Website von Apogee verfügbar sein.
- Upcoming presentation of Phase 1 clinical trial data for APG777
- APG777 demonstrates extended half-life and sustained inhibition of inflammatory biomarkers
- None.
SAN FRANCISCO and WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced an upcoming poster presentation at the American College of Allergy, Asthma & Immunology’s (ACAAI) 2024 Annual Scientific Meeting, held in Boston from October 24-28, 2024. The company plans to present data up to 9 months from the ongoing Phase 1 clinical trial of APG777, a novel half-life extended anti-IL-13 antibody for the treatment for atopic dermatitis and other inflammatory diseases.
Title: APG777, anti-IL-13 monoclonal antibody, demonstrates extended half-life and sustained inhibition of Type 2 inflammatory biomarkers
Abstract ID: R162
Authors: Xiu Qin Lim, M.B.B.S., Erica Winter, Pharm.D., Kristine Nograles, M.D., Sai Thankamony, Ph.D., Lukas Dillinger, Ph.D., Carl Dambkowski, M.D.
Date/Time: Friday, October 25, 2:00-6:00 p.m. ET
Location: Hynes Convention Center – Boston, Hall A
Full session details can be accessed on the ACAAI website. The poster will be available on the publications page of the Apogee website on October 24.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, COPD and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://apogeetherapeutics.com.
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
Noel.Kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick
1AB Media
dan@1abmedia.com
FAQ
What is Apogee Therapeutics (APGE) presenting at the ACAAI 2024 Annual Scientific Meeting?
When and where will Apogee Therapeutics (APGE) present their poster at ACAAI 2024?
What are the key findings of Apogee Therapeutics' (APGE) APG777 clinical trial?
Where can investors find Apogee Therapeutics' (APGE) ACAAI 2024 poster after the presentation?
